Merck & Co., Inc. (MRK) Total Return CAGR:56.29%(TTM)
The total return cagr for Merck & Co., Inc. (MRK) is +56.29% over the latest trailing 12-month period. The comparable SPY value is +24.32%. Year-to-date total return is +14.46%. Total return includes price appreciation and reinvested dividends.
The total return cagr for Merck & Co., Inc. (MRK) stock is 56.29% over the past 12 months. The 3 year average growth rate is 5.80% and the 5 year cagr is 13.58%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of Merck & Co., Inc.'s investment performance.
MRK Total Return CAGR Chart
Merck & Co., Inc. (MRK)
MRK Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 917.81 | 1050.52 | +132.72 | +14.46% | +14.46% |
| 2025 | 836.02 | 917.81 | +81.78 | +9.78% | +9.78% |
| 2024 | 891.83 | 836.02 | -55.80 | -6.26% | -6.26% |
| 2023 | 883.03 | 891.83 | +8.80 | +1.00% | +1.00% |
| 2022 | 591.11 | 883.03 | +291.92 | +49.38% | +49.38% |
| 2021 | 580.59 | 591.11 | +10.52 | +1.81% | +1.81% |
| 2020 | 625.68 | 580.59 | -45.09 | -7.21% | -7.21% |
| 2019 | 511.77 | 625.68 | +113.91 | +22.26% | +22.26% |
| 2018 | 365.51 | 511.77 | +146.25 | +40.01% | +40.01% |
| 2017 | 370.98 | 365.51 | -5.47 | -1.47% | -1.47% |
| 2016 | 322.50 | 370.98 | +48.49 | +15.03% | +15.03% |
| 2015 | 335.44 | 322.50 | -12.95 | -3.86% | -3.86% |
| 2014 | 286.81 | 335.44 | +48.64 | +16.96% | +16.96% |
| 2013 | 226.21 | 286.81 | +60.59 | +26.79% | +26.79% |
| 2012 | 199.96 | 226.21 | +26.26 | +13.13% | +13.13% |
| 2011 | 182.55 | 199.96 | +17.40 | +9.53% | +9.53% |
| 2010 | 177.43 | 182.55 | +5.12 | +2.89% | +2.89% |
| 2009 | 140.02 | 177.43 | +37.41 | +26.72% | +26.72% |
| 2008 | 256.16 | 140.02 | -116.13 | -45.34% | -45.34% |
| 2007 | 186.47 | 256.16 | +69.69 | +37.37% | +37.37% |
| 2006 | 130.71 | 186.47 | +55.76 | +42.66% | +42.66% |
| 2005 | 125.66 | 130.71 | +5.06 | +4.02% | +4.02% |
| 2004 | 173.92 | 125.66 | -48.26 | -27.75% | -27.75% |
| 2003 | 196.20 | 173.92 | -22.29 | -11.36% | -11.36% |
| 2002 | 198.70 | 196.20 | -2.50 | -1.26% | -1.26% |
| 2001 | 310.16 | 198.70 | -111.46 | -35.94% | -35.94% |
| 2000 | 218.76 | 310.16 | +91.40 | +41.78% | +41.78% |
| 1999 | 237.05 | 218.76 | -18.30 | -7.72% | -7.72% |
| 1998 | 167.33 | 237.05 | +69.73 | +41.67% | +41.67% |
| 1997 | 123.38 | 167.33 | +43.94 | +35.62% | +35.62% |
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis